Reality Check on Alpha-1 Antitrypsin Deficiency
Market access for alpha-1 antitrypsin deficiency treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Among the four medications covered under the medical benefit, only 16% of the lives have utilization management restrictions under Medicare policies
- Class Trends: The FDA allowed marketing of 23and Me, Inc's Personal Genome Service Genetic Health Risk tests. The tests look for generic variants in a person's saliva whose presence or absence can indicate a heightened risk for 10 conditions, including alpha-1 antitrypsin deficiency
- Key Findings: This is a consolidated market where coverage is at parity and health plans view products as undifferentiated
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.